Meeder Asset Management’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-15
| Closed | -$18 | – | 806 |
|
|
2023
Q4 | $18 | Hold |
15
| – | – | ﹤0.01% | 454 |
|
|
2023
Q3 | $72 | Hold |
15
| – | – | ﹤0.01% | 479 |
|
|
2023
Q2 | $58 | Hold |
15
| – | – | ﹤0.01% | 498 |
|
|
2023
Q1 | $38 | Hold |
15
| – | – | ﹤0.01% | 590 |
|
|
2022
Q4 | $27 | Sell |
15
-1
| -6% | -$5 | ﹤0.01% | 786 |
|
|
2022
Q3 | $0 | Sell |
16
-976
| -98% | -$11.7K | ﹤0.01% | 2438 |
|
|
2022
Q2 | $10K | Buy |
992
+279
| +39% | +$3.85K | ﹤0.01% | 1391 |
|
|
2022
Q1 | $16K | Buy |
+713
| New | +$14K | ﹤0.01% | 1383 |
|
|
2021
Q4 | – | Sell |
-644
| Closed | -$41K | – | 2515 |
|
|
2021
Q3 | $41K | Buy |
644
+133
| +26% | +$8.2K | ﹤0.01% | 1158 |
|
|
2021
Q2 | $41K | Buy |
511
+362
| +243% | +$30.2K | ﹤0.01% | 1199 |
|
|
2021
Q1 | $19K | Buy |
+149
| New | +$22.8K | ﹤0.01% | 1428 |
|
|
2020
Q4 | – | Sell |
-40
| Closed | -$4K | – | 2351 |
|
|
2020
Q3 | $4K | Hold |
40
| – | – | ﹤0.01% | 1689 |
|
|
2020
Q2 | $5K | Buy |
40
+22
| +122% | +$2.49K | ﹤0.01% | 1549 |
|
|
2020
Q1 | $1K | Sell |
18
-13
| -42% | -$2.12K | ﹤0.01% | 2265 |
|
|
2019
Q4 | $9K | Buy |
31
+17
| +121% | +$3.43K | ﹤0.01% | 1604 |
|
|
2019
Q3 | $2K | Hold |
14
| – | – | ﹤0.01% | 2013 |
|
|
2019
Q2 | $5K | Buy |
+14
| New | +$5.89K | ﹤0.01% | 1689 |
|
Other funds holding ELOX
Meeder Asset Management's ELOX Position: Q1 2024 in Review
Meeder Asset Management sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q1 2024, closing a stake of 15 shares — an estimated $18 sold.
Meeder Asset Management first reported a position in ELOX in Q2 2019 and held it in 17 quarters. The position peaked at $41K in Q3 2021. 1 fund tracked by Wall St. Rank holds ELOX as of Q1 2024.
- Meeder Asset Management reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Meeder Asset Management sold 15 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $18.
- Meeder Asset Management first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 17 quarters.
- Meeder Asset Management's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $41K in Q3 2021.
- 1 fund tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q1 2024.
Based on Meeder Asset Management's 13F filing for Q1 2024, filed 7 May 2024.